BACKGROUND INFORMATION ON THE PROCEDURE 
1.  
Submission of the dossier 
The  applicant  Novartis  Europharm  Ltd.  submitted  on  8  February  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Exforge,  through  the  centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 14 December 2005.  
The legal basis for this application refers to:  
Article 10(b) of Directive 2001/83/EC, as amended – relating to applications new fixed combination 
products. 
The  application  submitted  is  a  complete  dossier:  composed  of  administrative  information,  complete 
quality  data,  non-clinical  and  clinical  data  based  on  applicants’  own  tests  and  studies  and/or 
bibliographic literature substituting/supporting certain test(s) or studies. 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  
Steffen Thirstrup 
Co-Rapporteur: Alar Irs 
2.  
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 8 February 2006. 
The procedure started on 1 March 2006. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  22  May 
2006  (Annex  4.1).  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 19 May 2006.  
During  the  meeting  on  26-28  June  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 29 June 2006. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 9 August 
2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 26 September 2006. 
During  the  CHMP  meeting  on  16  –  18  October  2006,  the  CHMP  agreed  on  a  List  of 
Outstanding Issues to be addressed in writing by the applicant. 
The applicant submitted the responses to the CHMP consolidated List of Outstanding Issues on 
24 October 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 1 November 2006. 
During  the  meeting  on  13  –  16  November  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Exforge on 16 November 2006. The applicant provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  24 
October 2006. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 17 January 2007. 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
